Thistechnology enables CRISPR homology-directed repair in cystic-fibrosismouse lungs and demonstrates gene editing efficiencies unattainablewith liver-tropic formulations. TranslatingSORT chemistry to oncology is straightforward: employing guide RNAtargeting driver oncogenes (e.g., KRAS-G12C) or resistance mediators(e.g., KEAP1) could potentially rewrite tumor genomes in situ. Here, KRAS is linked to neoplasm.